Literature DB >> 12819914

Currently used non-specific extracellular MR contrast media.

M F Bellin1, M Vasile, S Morel-Precetti.   

Abstract

Magnetic resonance contrast agents have demonstrated their clinical usefulness in a variety of organs for improved detection of various neoplastic, inflammatory and functional abnormalities. Gadolinium chelates are the most widely used. They are extracellular, non-specific contrast agents. Their use in many clinical indications is justified because, in conjunction with improved imaging techniques, these safe and image-enhancing contrast agents add morphologic and functional information compared with unenhanced MR images. This article describes the commercially available compounds, and summarizes their approval status on the international market regarding indications and doses. Their mechanisms of action, biodistributions, toxicities and tolerance profiles in normal and high-risk patient populations are described. Additionally, this article reviews the specific recommendations by the manufacturers for patients at risk. Finally, their main clinical applications are reviewed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819914     DOI: 10.1007/s00330-003-1912-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  51 in total

1.  MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.

Authors:  W T Yuh; D J Fisher; J D Engelken; G M Greene; Y Sato; T J Ryals; M R Crain; J C Ehrhardt
Journal:  Radiology       Date:  1991-08       Impact factor: 11.105

2.  Excretion of gadopentetate dimeglumine in human breast milk.

Authors:  U Schmiedl; K R Maravilla; R Gerlach; C A Dowling
Journal:  AJR Am J Roentgenol       Date:  1990-06       Impact factor: 3.959

3.  The relationship between thermodynamics and the toxicity of gadolinium complexes.

Authors:  W P Cacheris; S C Quay; S M Rocklage
Journal:  Magn Reson Imaging       Date:  1990       Impact factor: 2.546

4.  Endometrial carcinoma: assessment of myometrial invasion with plain and gadolinium-enhanced MR imaging.

Authors:  F Saez; A Urresola; J A Larena; J I Martín; J I Pijuán; J Schneider; E Ibáñez
Journal:  J Magn Reson Imaging       Date:  2000-09       Impact factor: 4.813

Review 5.  Non-invasive vascular imaging: assessing tumour vascularity.

Authors:  S Delorme; M V Knopp
Journal:  Eur Radiol       Date:  1998       Impact factor: 5.315

6.  Safety of ProHance in special populations.

Authors:  K Yoshikawa; A Davies
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

7.  Worldwide clinical safety assessment of gadoteridol injection: an update.

Authors:  V M Runge; J R Parker
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

8.  Quantitative analysis of gadopentetate dimeglumine excreted in breast milk.

Authors:  N M Rofsky; J C Weinreb; A W Litt
Journal:  J Magn Reson Imaging       Date:  1993 Jan-Feb       Impact factor: 4.813

Review 9.  Three-dimensional gadolinium-enhanced MR angiography: applications for abdominal imaging.

Authors:  J F Glockner
Journal:  Radiographics       Date:  2001 Mar-Apr       Impact factor: 5.333

Review 10.  Value of 1.0- M gadolinium chelates: review of preclinical and clinical data on gadobutrol.

Authors:  Bernd Tombach; Walter Heindel
Journal:  Eur Radiol       Date:  2002-02-21       Impact factor: 5.315

View more
  26 in total

Review 1.  Imaging the lymphatic system: possibilities and clinical applications.

Authors:  Olivier Clément; Alain Luciani
Journal:  Eur Radiol       Date:  2004-03-09       Impact factor: 5.315

Review 2.  Safety of MR liver specific contrast media.

Authors:  Marie-France Bellin; Judith A W Webb; Aart J Van Der Molen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

Review 3.  Nephrogenic systemic fibrosis: a concise review for cardiologists.

Authors:  Benjamin Y C Cheong; Raja Muthupillai
Journal:  Tex Heart Inst J       Date:  2010

Review 4.  Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children.

Authors:  Lesley J Scott
Journal:  Clin Drug Investig       Date:  2013-04       Impact factor: 2.859

5.  Repeated intravenous administration of gadobutrol does not lead to increased signal intensity on unenhanced T1-weighted images-a voxel-based whole brain analysis.

Authors:  Soenke Langner; Marie-Luise Kromrey; Jens-Peter Kuehn; Matthias Grothe; Martin Domin
Journal:  Eur Radiol       Date:  2017-03-13       Impact factor: 5.315

6.  3D fiber tractography with susceptibility tensor imaging.

Authors:  Chunlei Liu; Wei Li; Bing Wu; Yi Jiang; G Allan Johnson
Journal:  Neuroimage       Date:  2011-08-16       Impact factor: 6.556

7.  Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol.

Authors:  Dragan A Stojanov; Aleksandra Aracki-Trenkic; Slobodan Vojinovic; Daniela Benedeto-Stojanov; Srdjan Ljubisavljevic
Journal:  Eur Radiol       Date:  2015-06-25       Impact factor: 5.315

Review 8.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

9.  Molecular imaging without radiopharmaceuticals?

Authors:  John C Gore; Thomas E Yankeelov; Todd E Peterson; Malcolm J Avison
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

10.  Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging.

Authors:  Zhen Ye; Xueming Wu; Mingqian Tan; Jack Jesberger; Mark Grisworld; Zheng-Rong Lu
Journal:  Contrast Media Mol Imaging       Date:  2013 May-Jun       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.